65 related articles for article (PubMed ID: 16224274)
1. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
[TBL] [Abstract][Full Text] [Related]
2. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
Luetkens T; Kobold S; Cao Y; Ristic M; Schilling G; Tams S; Bartels BM; Templin J; Bartels K; Hildebrandt Y; Yousef S; Marx A; Haag F; Bokemeyer C; Kröger N; Atanackovic D
Cancer Immunol Immunother; 2014 Nov; 63(11):1151-62. PubMed ID: 25078248
[TBL] [Abstract][Full Text] [Related]
3. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
de Carvalho F; Alves VL; Braga WM; Xavier CV; Colleoni GW
Cancer Immunol Immunother; 2013 Jan; 62(1):191-5. PubMed ID: 23180015
[TBL] [Abstract][Full Text] [Related]
4. EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Neumann F; Kaddu-Mulindwa D; Widmann T; Preuss KD; Held G; Zwick C; Roemer K; Pfreundschuh M; Kubuschok B
Cancer Immunol Immunother; 2013 Jul; 62(7):1211-22. PubMed ID: 23619976
[TBL] [Abstract][Full Text] [Related]
5. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.
Alves PM; Lévy N; Bouzourene H; Viatte S; Bricard G; Ayyoub M; Vuilleumier H; Givel JC; Halkic N; Speiser DE; Romero P; Lévy F
Cancer Immunol Immunother; 2007 Jun; 56(6):839-47. PubMed ID: 16960690
[TBL] [Abstract][Full Text] [Related]
6. Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification.
Naka N; Joyama S; Tsukamoto Y; Yoshioka K; Hashimoto N; Ujiiye T; Hayashi T; Kawase M; Mano M; Ishiguro S; Myoui A; Ueda T; Yoshikawa H; Araki N; Itoh K
J Mol Diagn; 2005 May; 7(2):187-97. PubMed ID: 15858142
[TBL] [Abstract][Full Text] [Related]
7. Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma.
Zhou FL; Zhang WG; Chen G; Zhao WH; Cao XM; Chen YX; Tian W; Liu J; Liu SH
Cancer Immunol Immunother; 2006 Aug; 55(8):910-7. PubMed ID: 16193335
[TBL] [Abstract][Full Text] [Related]
8. Microarray-based understanding of normal and malignant plasma cells.
De Vos J; Hose D; Rème T; Tarte K; Moreaux J; Mahtouk K; Jourdan M; Goldschmidt H; Rossi JF; Cremer FW; Klein B
Immunol Rev; 2006 Apr; 210():86-104. PubMed ID: 16623766
[TBL] [Abstract][Full Text] [Related]
9. Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells.
Danilova A; Misyurin V; Novik A; Girdyuk D; Avdonkina N; Nekhaeva T; Emelyanova N; Pipia N; Misyurin A; Baldueva I
Clin Sarcoma Res; 2020; 10():3. PubMed ID: 32042403
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.
Andrade VC; Vettore AL; Felix RS; Almeida MS; Carvalho F; Oliveira JS; Chauffaille ML; Andriolo A; Caballero OL; Zago MA; Colleoni GW
Cancer Immun; 2008 Feb; 8():2. PubMed ID: 18237105
[TBL] [Abstract][Full Text] [Related]
11. Higher Expression Levels of
Alrubie TM; Alamri AM; Almutairi BO; Alrefaei AF; Arafah MM; Alanazi M; Semlali A; Almutairi MH
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241221
[No Abstract] [Full Text] [Related]
12. Targeting cancer testis antigens in synovial sarcoma.
Mitchell G; Pollack SM; Wagner MJ
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083416
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunoprevention: Current Status and Future Directions.
Keshavarz-Fathi M; Rezaei N
Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):3. PubMed ID: 33638703
[TBL] [Abstract][Full Text] [Related]
14. Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.
Ait-Tahar K; Anderson AP; Barnardo M; Collins GP; Hatton CSR; Banham AH; Pulford K
Adv Hematol; 2017; 2017():6527306. PubMed ID: 29204156
[TBL] [Abstract][Full Text] [Related]
15. Dendritic Cell Therapies for Hematologic Malignancies.
Weinstock M; Rosenblatt J; Avigan D
Mol Ther Methods Clin Dev; 2017 Jun; 5():66-75. PubMed ID: 28480306
[TBL] [Abstract][Full Text] [Related]
16. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.
Bloom JE; McNeel DG
Oncotarget; 2016 Aug; 7(32):50997-51011. PubMed ID: 27276714
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.
Ghafouri-Fard S; Seifi-Alan M; Shamsi R; Esfandiary A
Iran J Cancer Prev; 2015 Oct; 8(5):e3755. PubMed ID: 26634107
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells.
D'Arcy P; Maruwge W; Wolahan B; Ma L; Brodin B
PLoS One; 2014; 9(4):e95136. PubMed ID: 24787708
[TBL] [Abstract][Full Text] [Related]
19. Expression of cancer-testis antigen in multiple myeloma.
He L; Ji JN; Liu SQ; Xue E; Liang Q; Ma Z
J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):181-185. PubMed ID: 24710929
[TBL] [Abstract][Full Text] [Related]
20. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
